GlassScriptPhysician profile
Nick M Ungson
NPI 1750431433
$4,312.05
in general payments reported to CMS, 2019-2025
18 companies · $647 in 2025
The $647 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $323 · 2020: $553 · 2021: $1,015 · 2022: $823 · 2023: $493 · 2024: $459 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,573 · Education: $25.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,573.33 |
| Education | $25.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.58 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $662.00 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $507.54 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $479.59 | 2020-2025 | Caplyta |
| Allergan, INC. | $345.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $320.69 | 2020-2025 | Spravato |
| Lundbeck LLC | $244.66 | 2019-2023 | Rexulti |
| Alkermes, INC. | $217.63 | 2022-2025 | Lybalvi, Aristada |
| Neurocrine Biosciences, INC. | $189.64 | 2022-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $182.05 | 2019-2025 | Fanapt |
| Sunovion Pharmaceuticals INC. | $173.47 | 2020-2022 | |
| Axsome Therapeutics, INC. | $43.16 | 2025 | Auvelity |
| Corium, LLC | $38.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $26.73 | 2025 | Cobenfy |
| Bausch Health US, LLC | $25.42 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $19.69 | 2021 | |
| Sage Therapeutics, LLC | $19.03 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nick Ungson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.